Last update 09 Dec 2025
Alphapharm Pty Ltd.

Alphapharm Pty Ltd.

Subsidiary Company|1982|Australia|
500-1,000
|
www.alphapharm.com.au

Overview

Tags

Respiratory Diseases
Infectious Diseases
Other Diseases
Small molecule drug
Biosimilar
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases6
Immune System Diseases3
Infectious Diseases3
Endocrinology and Metabolic Disease3
Hemic and Lymphatic Diseases2
Neoplasms2
Top 5 Drug TypeCount
Small molecule drug11
Biosimilar3
Hormone1
Colony-stimulating factors1
Monoclonal antibody1
Top 5 TargetCount
SERT(Serotonin transporter)2
GABAA receptor(Gamma-aminobutyric acid A receptor)2
nAChRs(Nicotinic receptors)1
PRKAB1 x SUR11
H1 receptor(Histamine H1 receptor)1

Related

14
Drugs associated with Alphapharm Pty Ltd.
Fluticasone propionate/Salmeterol xinafoate
Target
GR x cPLA2α x β2-adrenergic receptor
Mechanism
GR agonists [+2]
Active Org.
GSK PlcGSK Plc [+9]
Originator Org.
GSK PlcGSK Plc
Active Indication
Airway Obstruction [+4]
Inactive Indication
airway disease [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date24 Aug 2000
Glyburide/Metformin Hydrochloride
Target
PRKAB1 x SUR1
Mechanism
PRKAB1 activators [+1]
Active Org.
Alphapharm Pty Ltd.Alphapharm Pty Ltd. [+1]
Originator Org.
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Active Indication
Diabetes Mellitus [+1]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date31 Jul 2000
Loratadine
Target
H1 receptor
Mechanism
H1 receptor antagonists
Active Org.
Bayer AGBayer AG [+5]
Originator Org.
Merck & Co., Inc.Merck & Co., Inc.
Active Indication
Allergic skin reaction [+8]
Inactive Indication
Congestion of nasal mucosa [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date12 Apr 1993
1
Clinical Trials associated with Alphapharm Pty Ltd.
ACTRN12607000269437
/ Not yet recruitingPhase 4
Combination of Organic Nitrates and Hydralazine in the Management of Symptoms in Patients With Systolic Heart Failure Receiving Contemporary Neurohormonal Inhibition.
100 Clinical Results associated with Alphapharm Pty Ltd.
Login to view more data
0 Patents (Medical) associated with Alphapharm Pty Ltd.
Login to view more data
100 Deals associated with Alphapharm Pty Ltd.
Login to view more data
100 Translational Medicine associated with Alphapharm Pty Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
14
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free